US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicus Pharma Ltd.

3.38

+0.16004.97%

Post-market: 3.380.00000.00%15:39 EDT

Volume:355.95K

Turnover:1.21M

Market Cap:53.86M

PE:- -

High:3.59

Open:3.39

Low:3.30

Close:3.22

Loading ...

Overview Company News Filings

Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer

Medicus Pharma Ltd: Strategic Growth through Acquisition and Innovation Fuels Buy Rating

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd - to Buy Antev for 2.67 Mln Shares- SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd. to Acquire Antev Ltd., Offering 17% Equity Stake and Up to $65 Million in Contingent Payments

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Appoints Andrew Smith as Chief Operating Officer Amidst Clinical Development Expansion

Medicus Pharma Ltd. Secures $5 Million Debenture Agreement with Yorkville

Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Submits Product Development Plan to FDA for Treating Squamous Cell Carcinoma in Horses with D-MNA Patch

Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over "Going Concern" Status

Medicus Pharma Ltd. Completes $7 Million Public Offering to Fund Basal Cell Carcinoma Clinical Trials

Quantum Biopharma Receives $2.35 Million USD From a Mutually-Agreed Global Legal Settlement With DR. Raza Bokhari

THOMSON REUTERS

Medicus Pharma Ltd. Announces $7 Million Public Offering of Shares and Warrants

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd - Files for of Offering 1.4 Mln Units - SEC Filing

THOMSON REUTERS

BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares

Medicus Pharma Ltd: Files for Resale From Time to Time of up to 3.7 Mln Common Shares by Ya Ii Pn, Ltd-SEC Filing

THOMSON REUTERS

Medicus Pharma Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":3.38,"timestamp":1751562000000,"preClose":3.22,"halted":0,"volume":355954,"hourTrading":{"tag":"盘后","latestPrice":3.38,"preClose":3.38,"latestTime":"15:39 EDT","volume":2186,"amount":7385.9359,"timestamp":1751571554497},"delay":0,"floatShares":6964800,"shares":15933444,"eps":0,"marketStatus":"Closed Independence Day","change":0.16,"latestTime":"07-03 13:00:00 EDT","open":3.39,"high":3.5899,"low":3.3,"amount":1209724.280503,"amplitude":0.090031,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":3.22,"preHourTrading":{"tag":"盘前","latestPrice":3.42,"preClose":3.22,"latestTime":"09:27 EDT","volume":24997,"amount":84780.71759290001,"timestamp":1751549270056},"postHourTrading":{"tag":"盘后","latestPrice":3.38,"preClose":3.38,"latestTime":"15:39 EDT","volume":2186,"amount":7385.9359,"timestamp":1751571554497},"volumeRatio":1.9035045288811208},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":6964800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.9035045288811208,"shares":15933444,"dividePrice":0,"high":3.5899,"amplitude":0.090031,"preClose":3.22,"low":3.3,"week52Low":1.8,"pbRate":"--","week52High":8.94,"institutionHeld":0,"latestPrice":3.38,"eps":0,"divideRate":0,"volume":355954,"delay":0,"ttmEps":0,"open":3.39,"prevYearClose":2.43,"prevWeekClose":2.9,"prevMonthClose":2.99,"prevQuarterClose":2.99,"fiveDayClose":3.1,"twentyDayClose":2.75,"sixtyDayClose":3.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548179338","title":"Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2548179338","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548179338?lang=en_us&edition=fundamental","pubTime":"2025-07-04 06:37","pubTimestamp":1751582278,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing mentions Andrew Alasdair Smith as the beneficial owner, who serves as the Chief Operating Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDLLZpl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2548459384","title":"Medicus Pharma Ltd: Strategic Growth through Acquisition and Innovation Fuels Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2548459384","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548459384?lang=en_us&edition=fundamental","pubTime":"2025-07-04 02:15","pubTimestamp":1751566513,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-strategic-growth-through-acquisition-and-innovation-fuels-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-strategic-growth-through-acquisition-and-innovation-fuels-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2548883311","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2548883311","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548883311?lang=en_us&edition=fundamental","pubTime":"2025-07-01 23:34","pubTimestamp":1751384040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2025 11:34 ET (15:34 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2548330014","title":"Medicus Pharma Ltd - to Buy Antev for 2.67  Mln Shares- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548330014?lang=en_us&edition=fundamental","pubTime":"2025-07-01 01:52","pubTimestamp":1751305939,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX0YR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2547950650","title":"Medicus Pharma Ltd. to Acquire Antev Ltd., Offering 17% Equity Stake and Up to $65 Million in Contingent Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2547950650","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547950650?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:31","pubTimestamp":1751283064,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the terms of the agreement, Medicus will acquire all issued and outstanding shares of Antev in exchange for approximately 17% of Medicus's common shares. Antev shareholders are also eligible to receive up to $65 million in additional contingent payments, dependent on future FDA Phase 2 and New Drug Application approvals. The transaction is anticipated to close by the end of August 2025, pending the fulfillment of closing conditions, including Antev shareholder approval. Antev is currently focused on developing Teverelix, a GnRH antagonist, for treating cardiovascular high-risk prostate cancer and acute urinary retention.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL56P3p8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2545557417","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2545557417","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545557417?lang=en_us&edition=fundamental","pubTime":"2025-06-23 21:29","pubTimestamp":1750685340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2025 09:29 ET (13:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2545416251","title":"Medicus Pharma Ltd. Appoints Andrew Smith as Chief Operating Officer Amidst Clinical Development Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2545416251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545416251?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:31","pubTimestamp":1750678290,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the appointment of Andrew Smith as Chief Operating Officer. Andrew brings over three decades of experience in asset management and financial operations, having previously served as Chief Executive of SR Asset Management and Co-Head of Americas at Aberdeen Asset Management Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL5Zy9Fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABDN.UK","MDCX"],"gpt_icon":0},{"id":"2545170752","title":"Medicus Pharma Ltd. Secures $5 Million Debenture Agreement with Yorkville","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170752?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:21","pubTimestamp":1750450874,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd., an Ontario-based company, has announced the entry into a significant securities purchase agreement with YA II PN, Ltd. . Under this agreement, Medicus Pharma will issue debentures totaling up to $5 million, with Yorkville having already purchased debentures worth $5 million in aggregate principal. The company has received net proceeds of $4.5 million from these transactions. The debentures, which mature on February 2, 2026, carry an annual interest rate of 8%, potentially increasing to 18% in case of specific defaults. The debentures are backed by a global guaranty agreement involving the company's subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLb7KtvT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2542151667","title":"Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151667","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151667?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:31","pubTimestamp":1749727878,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the signing of a binding letter of intent to acquire Antev Ltd., a UK-based late clinical stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at providing a first-in-market treatment for cardiovascular high-risk advanced prostate cancer patients and those experiencing first acute urinary retention relapse episodes due to an enlarged prostate. This acquisition marks a significant step for Medicus Pharma in expanding its portfolio and strengthening its position in the biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 12, 2025, and is solely res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6bRCRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2542333762","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2542333762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542333762?lang=en_us&edition=fundamental","pubTime":"2025-06-09 22:47","pubTimestamp":1749480420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2025 10:47 ET (14:47 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2542056389","title":"Medicus Pharma Ltd. Submits Product Development Plan to FDA for Treating Squamous Cell Carcinoma in Horses with D-MNA Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2542056389","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542056389?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:31","pubTimestamp":1749468665,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the submission of a comprehensive product development plan to the Food and Drug Administration  to treat external squamous cell carcinoma  in horses. This plan involves the use of a novel Doxorubicin-containing microneedle array  patch, which in December 2024 received a Minor Use in Major Species Designation . The submission aims to seek the FDA's concurrence under the MUMS designation, advancing the company's efforts in veterinary oncology. This development is part of Medicus Pharma's broader initiative to innovate treatment options in veterinary medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL4VtW0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2541300581","title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2541300581","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541300581?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:06","pubTimestamp":1749153971,"startTime":"0","endTime":"0","summary":"**Medicus Pharma Ltd. Announces Change in Certifying Accountants Amidst Financial Concerns** June 5, 2025 - Medicus Pharma Ltd. has announced the dismissal of EisnerAmper LLP as its independent registered public accounting firm, following a recommendation by the company's audit committee and approval by the board of directors. The decision comes after EisnerAmper raised concerns about the company's ability to continue as a going concern due to negative cash flows and operating losses. EisnerAmper's report for the fiscal year ending December 31, 2024, highlighted substantial doubt about Medicus Pharma's financial stability, although it did not issue an adverse opinion or disclaimer. Despite these concerns, there were no disagreements between the company and EisnerAmper on accounting principles or practices. KPMG LLP has been appointed as the new independent registered public accounting firm, with EisnerAmper authorized to fully cooperate with the transition. This change follows disclosu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3r0Zlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2540797434","title":"Medicus Pharma Ltd. Completes $7 Million Public Offering to Fund Basal Cell Carcinoma Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2540797434","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540797434?lang=en_us&edition=fundamental","pubTime":"2025-06-03 01:41","pubTimestamp":1748886066,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has successfully closed its public offering, raising $7.0 million. The company issued 2,260,000 units at a price of $3.10 per unit, with each unit comprising one common share and one warrant to purchase an additional share. The warrants have an exercise price of $3.10 and will expire in five years. Maxim Group LLC served as the lead placement agent, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The proceeds from the offering are intended to fund a Phase 2 clinical trial for basal cell carcinoma treatment using a dissolvable microarray needle skin patch, with potential expansion to other skin disease trials and general corporate purposes. The common shares are traded under the symbol \"MDCX\" on the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL5xnfpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2539267752","title":"Quantum Biopharma Receives $2.35 Million USD From a Mutually-Agreed Global Legal Settlement With DR. Raza Bokhari","url":"https://stock-news.laohu8.com/highlight/detail?id=2539267752","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539267752?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:00","pubTimestamp":1748602800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5SVMQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2539297934","title":"Medicus Pharma Ltd. Announces $7 Million Public Offering of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2539297934","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539297934?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:31","pubTimestamp":1748565070,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the pricing of its public offering, raising $7.0 million through the issuance of 2,260,000 units at $3.10 per unit. Each unit includes one common share and one warrant, which can be exercised to purchase an additional common share at the same price within five years. The offering is led by Maxim Group LLC, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The common shares are listed on NASDAQ under the symbol \"MDCX,\" while the warrants will not be traded on any securities exchange. Proceeds from this offering are earmarked for advancing the company's clinical trials related to basal cell carcinoma and potentially expanding trials to other non-melanoma skin diseases, with remaining funds allocated for general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1TW9s7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2539268413","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2539268413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539268413?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:54","pubTimestamp":1748523240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2025 08:54 ET (12:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2538923674","title":"Medicus Pharma Ltd - Files for of Offering 1.4 Mln Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2538923674","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538923674?lang=en_us&edition=fundamental","pubTime":"2025-05-28 05:00","pubTimestamp":1748379625,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ1ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2538496538","title":"BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2538496538","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538496538?lang=en_us&edition=fundamental","pubTime":"2025-05-28 01:34","pubTimestamp":1748367272,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common SharesMay 27 (Reuters) - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD: FILES FOR RESALE FROM TIME TO TIME OF UP TO 3.7 MILLION COMMON SHARES BY YA II PN, LTD-SEC FILING ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ142:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2538449501","title":"Medicus Pharma Ltd: Files for Resale From Time to Time of up to 3.7 Mln Common Shares by Ya Ii Pn, Ltd-SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2538449501","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538449501?lang=en_us&edition=fundamental","pubTime":"2025-05-28 01:20","pubTimestamp":1748366454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ142:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2537946486","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2537946486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537946486?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:28","pubTimestamp":1747916880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2025 08:28 ET (12:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744689600000}}}